ASX:CYC - Cyclopharm Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
A$1.30 +0.04 (+3.19 %)
(As of 05/22/2019 01:25 PM ET)
Previous CloseA$1.25
Today's RangeA$1.30 - A$1.30
52-Week RangeA$0.85 - A$1.30
Volume3,000 shs
Average VolumeN/A
Market Capitalization$88.97 million
P/E RatioN/A
Dividend Yield0.91%
Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism. It also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases; and Ultralute, a patented nuclear medicine technology for use in Mollybdenum-99 generators. The company serves nuclear medicine departments in hospitals and clinics. Cyclopharm Limited is headquartered in Kingsgrove, Australia.

Receive CYC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices
Phone61 2 9541 0411



Sales & Book Value

Annual Sales$15.53 million
Cash FlowA$0.09 per share
Book ValueA$0.25 per share



Market Cap$88.97 million
Next Earnings DateN/A
OptionableNot Optionable

Cyclopharm (ASX:CYC) Frequently Asked Questions

What is Cyclopharm's stock symbol?

Cyclopharm trades on the ASX under the ticker symbol "CYC."

How often does Cyclopharm pay dividends? What is the dividend yield for Cyclopharm?

Cyclopharm declared a Final dividend on Friday, March 1st. Investors of record on Monday, April 15th will be paid a dividend of 0.005 per share on Monday, April 15th. This represents a dividend yield of 0.42%. The ex-dividend date is Friday, April 5th. View Cyclopharm's Dividend History.

Has Cyclopharm been receiving favorable news coverage?

Media stories about CYC stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cyclopharm earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Cyclopharm's key competitors?

Who are Cyclopharm's key executives?

Cyclopharm's management team includes the folowing people:
  • Mr. James S. McBrayer, CEO, MD, Company Sec. & Director (Age 54)
  • Mr. Mathew Farag, Chief Operating Officer
  • Mr. Graham N. Phillips, Fin. Mang.
  • Ms. Sui Ling Cheah, Financial Controller (Age 49)
  • Mr. Lynn McLauchlin, Gen. Mang. of Canada

What is Cyclopharm's stock price today?

One share of CYC stock can currently be purchased for approximately A$1.30.

How big of a company is Cyclopharm?

Cyclopharm has a market capitalization of $88.97 million and generates $15.53 million in revenue each year.

What is Cyclopharm's official website?

The official website for Cyclopharm is

How can I contact Cyclopharm?

The company can be reached via phone at 61 2 9541 0411.

MarketBeat Community Rating for Cyclopharm (ASX CYC)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  5
MarketBeat's community ratings are surveys of what our community members think about Cyclopharm and other stocks. Vote "Outperform" if you believe CYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel